AstraZeneca Files Visacor, Axalin As Tradenames For Cardio Therapies
This article was originally published in Pharmaceutical Approvals Monthly
AstraZeneca is expanding the list of potential tradenames for its cardiovascular pipeline with the submission of the names Visacor and Axalin to the Patent and Trademark Office for approval.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class